


Lomitapide mesylate

Cat. No.:	HY-14668
CAS No.:	202914-84-9
Molecular Formula:	C ₄₀ H ₄₁ F ₆ N ₃ O ₅ S
Molecular Weight:	789.83
Target:	Microsomal Triglyceride Transfer Protein (MTP)
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (126.61 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions	1 mM	1 mg	5 mg	10 mg
		5 mM	1.2661 mL	6.3305 mL	12.6610 mL
		10 mM	0.2532 mL	1.2661 mL	2.5322 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.17 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.17 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.17 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Lomitapide mesylate(AEGR-733; BMS-201038) is an inhibitor of microsomal triglyceride-transfer protein (MTP) with in vitro IC50 of 8 nM. IC50 value: 8 nM [1] Target: MTP inhibitor Lomitapide is a small-molecule, microsomal triglyceride transfer protein (MTP) inhibitor, for the treatment of both familial and primary hypercholesterolemia. Oral, once-daily lomitapide will be targeted at patients resistant to HMG-CoA reductase inhibitors (statins) either due to abnormalities in liver function or to discontinuation because of muscle pain.
--------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CUSTOMER VALIDATION

-
- Free Radic Biol Med. 2021 Jun 8;S0891-5849(21)00353-1.
 - BMC Microbiol. 2022 Apr 26;22(1):114.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Sulsky R, et al. 5-Carboxamido-1,3,2-dioxaphosphorinanes, potent inhibitors of MTP. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5067-70.
- [2]. Lomitapide. Am J Cardiovasc Drugs. 2011 Oct 1;11(5):347-52.
- [3]. Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013 Aug;13(4):285-96.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA